EE66 Estimating the Costs of Familial Hypercholesterolemia Management Using Primary Claims Data

Abstract

Familial hypercholesterolemia is a rare genetic condition increasing an individual’s risk of cardiovascular disease. Early diagnosis and access to lipid-lowering treatment are essential to prevent stroke, heart attack, and cardiac death. Limited understanding of familial hypercholesterolemia costs to payers prevents the economic assessment of optimal screening and treatment strategies. We sought to measure the direct medical costs of diagnostic lipid panel testing and pharmacotherapy for familial hypercholesterolemia from real-world data.